Сергей Вялов - О чем молчит печень. Как уловить сигналы самого крупного внутреннего органа, который предпочитает оставаться в тени

4. Parkkila S., Niemela O., Britton R.S. et al. Molecular aspects of iron absorption and HFE expression. Gastroenterology . 2001 Dec. 121 (6): 1489–1496.

5. Allen K.J., Gurrin L.C., Constantine C.C. et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med . 2008 Jan 17. 358 (3): 221–230.

6. Janssen M.C., Swinkels D.W. Hereditary haemochromatosis. Best Pract Res Clin Gastroenterol . 2009. 23 (2): 171–183.

7. Gurrin L.C., Bertalli N.A., Dalton G.W. et al. HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-related morbidity. Hepatology . 2009 Jul. 50 (1): 94–101.

8. Brissot P. Optimizing the diagnosis and the treatment of iron overload diseases. Expert Rev Gastroenterol Hepatol . 2016. 10 (3): 359–370.

9. Dusek P., Roos P.M., Litwin T., Schneider S.A., Flaten T.P., Aaseth J. The neurotoxicity of iron, copper and manganese in Parkinson’s and Wilson’s diseases. J Trace Elem Med Biol . 2015 Jul. 31: 193–203.

10. Rodriguez-Castro K.I., Hevia-Urrutia F.J., Sturniolo G.C. Wilson’s disease: A review of what we have learned. World J Hepatol . 2015 Dec 18. 7 (29): 2859–2870.

11. Schilsky M.L. Wilson disease: diagnosis, treatment, and follow-up. Clin Liver Dis . 2017 Nov. 21 (4): 755–767.

12. Roberts E.A., Schilsky M.L. American Association for Study of Liver Diseases (AASLD). Diagnosis and treatment of Wilson disease: an update. Hepatology . 2008 Jun. 47 (6): 2089–2111.

13. Weiss K.H., Thurik F., Gotthardt D.N. et al. Efficacy and safety of oral chelators in treatment of patients with Wilson disease. Clin Gastroenterol Hepatol . 2013 Aug. 11 (8): 1028–1035.e2.

14. Gerosa C., Fanni D., Congiu T. et al. Liver pathology in Wilson’s disease: from copper overload to cirrhosis. J Inorg Biochem . 2019 Jan 15. 193: 106–111.

1. Solis Herruzo J.A., Solis Munoz P, Munoz Yague T. The pathogenesis of primary biliary cirrhosis. Rev Esp Enferm Dig . 2009 Jun. 101 (6): 413–423.

2. Selmi C., Gershwin M.E. The role of environmental factors in primary biliary cirrhosis. Trends Immunol . 2009 Aug. 30 (8): 415–420.

3. Lindor K., Dickson R. Primary biliary cirrhosis. Schiff ER, Sorrell MF, Maddrey WC, eds. Schiff’s Diseases of the Liver . 8th ed. Lippincott-Raven: Philadelphia; 1999. Vol 1: 679–692.

4. Pares A., Caballeria L., Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology . 2006 Mar. 130 (3): 715–720.

5. Ricci P, Therneau T.M., Malinchoc M. et al. A prognostic model for the outcome of liver transplantation in patients with cholestatic liver disease. Hepatology . 1997 Mar. 25 (3): 672–677.

1. Tsochatzis E.A., Bosch J., Burroughs A.K. Liver cirrhosis. Lancet . 2014 May 17. 383 (9930): 1749–1761.

2. Friedman S.L. Hepatic fibrosis. Schiff ER, Sorrell MF, Maddrey WC, eds. Schiff’s Diseases of the Liver . 8th ed. Philadelphia, Pa: Lippincott-Raven; 1999. 371–385.

3. Freeman R.B. Overview of the MELD/PELD system of liver allocation indications for liver transplantation in the MELD era: evidence-based patient selection. Liver Transpl . 2004 Oct. 10 (10 Suppl 2): S2–3.

4. [Guideline] European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol . 2018 Aug. 69 (2): 406–460.

5. [Guideline] European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol . 2018 Jul. 69 (1): 182–236.

6. Lubel J.S., Angus P.W. Modern management of portal hypertension. Intern Med J . 2005 Jan. 35 (1): 45–49.

7. Sanyal A.J., Bosch J., Blei A., Arroyo V. Portal hypertension and its complications. Gastroenterology . 2008 May. 134 (6): 1715–1728.

8. Kim T.Y., Jeong W.K., Sohn J.H., Kim J., Kim M.Y., Kim Y. Evaluation of portal hypertension by real-time shear wave elastography in cirrhotic patients. Liver Int . 2015 Nov. 35 (11): 2416–2424.

9. Sass D.A., Chopra K.B. Portal hypertension and variceal hemorrhage. Med Clin North Am . 2009 Jul. 93 (4): 837–853, vii-viii.

10. Arroyo V., Gines P., Gerbes A.L. et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology . 1996 Jan. 23 (1): 164–176.

11. Caldwell S.H., Battle E.H. Ascites and spontaneous bacterial peritonitis. Schiff ER, Sorrell MF, Maddrey WC, eds. Schiff’s Diseases of the Liver . 8th ed. Philadelphia, Pa: Lippincott-Raven; 1999. 371–385.

12. Kiser T.H., Maclaren R., Fish D.N. Treatment of hepatorenal syndrome. Pharmacotherapy . 2009 Oct. 29 (10): 1196–1211.

13. Hou W., Sanyal A.J. Ascites: diagnosis and management. Med Clin North Am . 2009 Jul. 93 (4): 801–817, vii.

14. Ahboucha S., Pomier-Layrargues G., Butterworth R.F. Increased brain concentrations of endogenous (non-benzodiazepine) GABA-A receptor ligands in human hepatic encephalopathy. Metab Brain Dis . 2004 Dec. 19 (3–4): 241–51.

15. Ahboucha S., Butterworth R.F. The neurosteroid system: an emerging therapeutic target for hepatic encephalopathy. Metab Brain Dis . 2007 Dec. 22 (3–4): 291–308.

16. Butterworth R.F. Neurosteroids in hepatic encephalopathy: Novel insights and new therapeutic opportunities. J Steroid Biochem Mol Biol . 2016 Jun. 160: 94–97.

17. Shawcross D.L., Dunk A.A., Jalan R. et al. How to diagnose and manage hepatic encephalopathy: a consensus statement on roles and responsibilities beyond the liver specialist. Eur J Gastroenterol Hepatol . 2016 Feb. 28 (2): 146–152.

18. Frederick R.T. Current concepts in the pathophysiology and management of hepatic encephalopathy. Gastroenterol Hepatol (N Y) . 2011 Apr. 7 (4): 222–233.

1. Onori P., Franchitto A., Mancinelli R. et al. Polycystic liver diseases. Dig Liver Dis . 2010 Apr. 42 (4): 261–271.

2. Choi H.K., Lee J.K., Lee K.H. et al. Differential diagnosis for intrahepatic biliary cystadenoma and hepatic simple cyst: significance of cystic fluid analysis and radiologic findings. J Clin Gastroenterol . 2010 Apr. 44 (4): 289–293.

3. Mazza O.M., Fernandez D.L., Pekolj J. et al. Management of nonparasitic hepatic cysts. J Am Coll Surg . 2009 Dec. 209 (6): 733–739.

4. Amendolara M., Bucca D., Barbarino C., Romano M.F., Marino G., Zucchelli M. et al. Surgical management of symptomatic simple hepatic cysts. G Chir . 2012 Jan-Feb. 33 (1–2): 17–20.

5. Schnelldorfer T., Torres V.E., Zakaria S. et al. Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation. Ann Surg . 2009 Jul. 250 (1): 112–118.

6. Dickie B., Dasgupta R., Nair R. et al. Spectrum of hepatic hemangiomas: management and outcome. J Pediatr Surg . 2009 Jan. 44 (1): 125–133.

7. Giannitrapani L., Soresi M., La Spada E. et al. Sex hormones and risk of liver tumor. Ann N Y Acad Sci . 2006 Nov. 1089: 228–236.

8. Bajenaru N., Balaban V., Savulescu F., Campeanu I., Patrascu T. Hepatic hemangioma – review-. J Med Life . 2015. 8 Spec Issue: 4–11.

9. Hasan H.Y., Hinshaw J.L., Borman E.J., Gegios A., Leverson G., Winslow E.R. Assessing normal growth of hepatic hemangiomas during long-term follow-up. JAMA Surg . 2014 Dec. 149 (12): 1266–1271.